Related Experiment Videos
Topiramate blocks perinatal hypoxia-induced seizures in rat pups
1Department of Neurology, Children's Hospital, Harvard Medical School, Boston, MA, USA.
Insights
Topiramate effectively suppressed neonatal seizures caused by hypoxia in a rat model. This anticonvulsant prevented long-term seizure susceptibility and brain injury, suggesting potential for treating refractory neonatal seizures.
Area of Science:
- Neuroscience
- Pharmacology
- Neonatal Medicine
Background:
- Neonatal seizures due to hypoxia are often resistant to standard treatments.
- Hypoxic encephalopathy in newborns can lead to severe, long-term neurological damage.
- Existing postnatal interventions for hypoxic encephalopathy are limited.
Purpose of the Study:
- To evaluate the efficacy of topiramate in a rat model of perinatal hypoxia-induced seizures.
- To determine if topiramate can prevent long-term increases in seizure susceptibility and neuronal injury.
Main Methods:
- A rat model of perinatal hypoxia-induced seizures was utilized.
- The anticonvulsant topiramate was administered in a dose-dependent manner.
- Long-term seizure susceptibility and neuronal injury were assessed after acute seizure suppression.
Main Results:
- Topiramate suppressed acute hypoxia-induced seizures effectively in a dose-related manner (ED50 = 2.1 mg/kg).
- Topiramate administration prevented the long-term increase in kainate-induced seizure susceptibility.
- Animals treated with topiramate showed no seizure-induced neuronal injury.
Conclusions:
- Topiramate demonstrates significant efficacy in suppressing acute neonatal seizures induced by hypoxia.
- Topiramate may serve as a potential therapeutic agent for refractory neonatal seizures.
- This study highlights topiramate's potential to prevent long-term neurological sequelae in neonates with hypoxic seizures.
Abstract:
Neonatal seizures caused by hypoxia can be refractory to conventional anticonvulsants. Currently, there is no effective postnatal intervention for newborn infants with hypoxic encephalopathy to prevent brain injury and long-term neurologic sequelae. We previously developed a rat model of perinatal hypoxia-induced seizures with subsequent long-term increases in seizure susceptibility and showed that these epileptogenic effects are selectively blocked by the alpha-amino-3-hydoxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonist 6-nitro-7-sulfamoylbenzo(f)quinoxaline-2,3-dione. Using this model of perinatal seizures, we evaluated the efficacy of topiramate, a structurally novel anticonvulsant drug recently shown to attenuate AMPA/kainate currents. Topiramate effectively suppressed acute seizures induced by perinatal hypoxia in a dose-related manner with a calculated ED50 of 2.1 mg/kg, i.p. Furthermore, in animals that had seizures suppressed by topiramate during acute hypoxia, there were no long-term increases in susceptibility to kainate-induced seizures and seizure-induced neuronal injury. Our results suggest that topiramate may have clinical potential as a therapeutic agent for refractory seizures in human neonates.